Wanjia (HKG:0401) expects a loss of around HK$5.8 million for the year ended March 31, down 86% from HK$40.3 million a year prior, a Thursday Hong Kong bourse filing said.
The pharmaceutical distribution company attributed the loss mainly to refunds of certain items related to hemodialysis treatment requested by a county medical security bureau in China from the firm's hemodialysis treatment centers.